Loading stock…

Aktis Oncology, Inc. (AKTS) Stock Verdict & Ratings | Investment Bastion

Stock Verdict·Updated today

Aktis Oncology, Inc.

AKTSMarket cap $0.99BPrice $17.7

Country🇺🇸United States

SectorHealthcare

IndustryBiotechnology

Develops precision radiopharmaceuticals that deliver radioactive isotopes directly to tumors while sparing healthy tissue. Its alpha-particle therapies target cancers other treatments can't touch, aiming to turn radiation into a scalpel, not a blast radius.

In Bastion Portfolios?

52W Return-30%

01Key Ratings

How does this stock score across Bastion factors?

Growth

Historical Revenue

Rev CAGR (3y)na–

Revenue Forecast

Rev CAGR (1y)+65%10

Rev CAGR (3y)+9%6

Rev CAGR (5y)+50%10

Earnings Forecast

EPS Growth Y+1Loss1

EPS Growth Y+2Loss1

EPS Growth Y+3Loss1

Quality

Margins

EBIT Margin-867%1

Net Income Margin-727%1

Free Cash Flow Margin-841%1

Debt

Net Debt/EBITDAna–

Efficiency

ROE-15%1

ROAna–

Earnings Stabilityna–

GEAR+VERY WEAK4

Overall rating across all five factors

Value

Price Multiples

P/E Ratio (Forward)na–

P/E Ratio (Forward 3y)na–

P/BV2.07

EV Multiples

EV/EBITDA Fwdna–

EV/EBIT Fwdna–

Yield

Free Cash Flow Yield-8.6%1

Dividend Yieldna–

Momentum

Short term

1 month return-26%1

3 month return-38%1

YTD return-21%2

Mid term

Price vs 52wHigh52%2

1 year return-21%2

Long term

3 year return-21%2

5 year return-21%3

Risk Shield

Price Risk

Betana–

Volatility68%2

Free Cash Flow

Free Cash Flow Margin-841%1

Free Cash Flow Yield-8.6%1

Quality

ROCE-33%1

Earnings Stabilityna–

Net Debt/EBITDAna–

02Growth

Is it actually growing, and how fast?

AKTSAktis Oncology

Revenue FY25$6M

GROWTH RATING↗

AVERAGE60 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGRna–

Revenue, next 1Y+65%10

Revenue, next 3Y, CAGR+9%6

Revenue, next 5Y, CAGR+50%10

EARNINGS FORECAST▾SCORE

EPS growth, FY26ELoss1

EPS growth, FY27ELoss1

EPS growth, FY28ELoss1

GROWTH ASSESSMENT

STRENGTHS

Revenue is set to grow 9%/yr over the next 3 years, ahead of most of the market.9/10

Revenue held flat over the last 3 years and is set to grow 9%/yr from here.

The runway holds up: revenue is set to grow 50%/yr over five years.10/10

WATCH

A mid-pack grower, ahead of 60% of companies worldwide.

WEAKNESSES

The company is loss-making, so its revenue growth is not backed by profit yet.

BOTTOM LINE

Top-Line Rocket

A middle-of-the-pack grower that's speeding up. The one thing to watch: the company is not profitable yet.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

VERY WEAK3 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-26%1

3-month return-38%1

YTD return-21%2

MID & LONG-TERM▾SCORE

% of 52-week high52%2

1-year return-21%2

3-year return-21%2

5-year return-21%3

MOMENTUM ASSESSMENT

STRENGTHS

None flagged.

WATCH

None flagged.

WEAKNESSES

Weak long-term results. It has been a disappointing long-term hold (-21% over three years and -21% over five), behind 70% of the market.

It's down 21% over the past year, now 48% below its 52-week high. That is lagging the market.

The stock is underperforming over the past month (-26%), over three months (-38%) and so far this year (-21%).

BOTTOM LINE

Falling Knife

Returns rank poorly over both the short and long run, and the price is still falling. Momentum is firmly negative — catching this is a bet against the tape, not with it. Wait for a base to form. The one thing to watch: the multi-year record is weak.

04Value

Are you paying a fair price for it?

Stop guessing on Aktis Oncology, Inc.. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

Loading charts…

02Growth

Is it actually growing, and how fast?

AKTSAktis Oncology

Revenue FY25$6M

GROWTH RATING↗

AVERAGE60 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGRna–

Revenue, next 1Y+65%10

Revenue, next 3Y, CAGR+9%6

Revenue, next 5Y, CAGR+50%10

EARNINGS FORECAST▾SCORE

EPS growth, FY26ELoss1

EPS growth, FY27ELoss1

EPS growth, FY28ELoss1

GROWTH ASSESSMENT

STRENGTHS

Revenue is set to grow 9%/yr over the next 3 years, ahead of most of the market.9/10

Revenue held flat over the last 3 years and is set to grow 9%/yr from here.

The runway holds up: revenue is set to grow 50%/yr over five years.10/10

WATCH

A mid-pack grower, ahead of 60% of companies worldwide.

WEAKNESSES

The company is loss-making, so its revenue growth is not backed by profit yet.

BOTTOM LINE

Top-Line Rocket

A middle-of-the-pack grower that's speeding up. The one thing to watch: the company is not profitable yet.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

VERY WEAK3 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-26%1

3-month return-38%1

YTD return-21%2

MID & LONG-TERM▾SCORE

% of 52-week high52%2

1-year return-21%2

3-year return-21%2

5-year return-21%3

MOMENTUM ASSESSMENT

STRENGTHS

None flagged.

WATCH

None flagged.

WEAKNESSES

Weak long-term results. It has been a disappointing long-term hold (-21% over three years and -21% over five), behind 70% of the market.

It's down 21% over the past year, now 48% below its 52-week high. That is lagging the market.

The stock is underperforming over the past month (-26%), over three months (-38%) and so far this year (-21%).

BOTTOM LINE

Falling Knife

04Value

Are you paying a fair price for it?

Stop guessing on Aktis Oncology, Inc.. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community